Jci_page_head_homepage_01 Jci_page_head_homepage_02
Koji Kishimoto, Victor M. Dong, Shohreh Issazadeh, Eugenia V. Fedoseyeva, Ana Maria Waaga, Akira Yamada, Masayuki Sho, Gilles Benichou, Hugh Auchincloss Jr., Michael J. Grusby, Samia J. Khoury, Mohamed H. Sayegh
Published in Volume 106, Issue 1
J Clin Invest. 2000; 106(1):63–72 doi:10.1172/JCI9586
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 7

Effect of MR1 or CTLA4Ig treatment on in vitro lymphocyte proliferation and cytokine production in mice immunized with OVA. The animals were immunized with OVA/CFA, and treatment started with CTLA4Ig or MR1 on the day of immunization and given every other day for five doses. Control mice received control Ig (CIg). Lymph nodes were collected on day 10 after immunization and proliferation (a), and cytokine production (b and c) was measured after stimulation with OVA in vitro at three doses: 25 μg/mL, shaded bar; 50 μg/mL, open bar; and 100 μg/mL, filled bar.